Added to YB: 2025-10-24
Pitch date: 2025-10-22
NVO [bullish]
Novo Nordisk A/S
-5.82%
current return
Author Info
Capitalist Letters simplifies investing and makes it understandable for everybody. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 341.00
Price Target
107.00 (-67%)
Dividend
3.64%
EV/EBITDA
8.92
P/E
13.70
EV/Sales
4.72
Sector
Pharmaceuticals
Category
value
5 Quality Stocks You Can Still Buy at Reasonable Prices - Novo Nordisk A/S
NVO: Misunderstood after Cagrisema delivered 22.7% weight loss vs 25% expected, matching Zepbound not beating it. Reality: superior pipeline w/ oral Wegovy (16.6% loss in 64wks vs Lilly's 12.4%), Amycretin (24.3% in 36wks vs Lilly's 24.2% in 48wks). DCF assuming 9% revenue growth shows 2x upside.
Read full article (2 min)